231 related articles for article (PubMed ID: 24371230)
1. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Green DJ; Orgun NN; Jones JC; Hylarides MD; Pagel JM; Hamlin DK; Wilbur DS; Lin Y; Fisher DR; Kenoyer AL; Frayo SL; Gopal AK; Orozco JJ; Gooley TA; Wood BL; Bensinger WI; Press OW
Cancer Res; 2014 Feb; 74(4):1179-89. PubMed ID: 24371230
[TBL] [Abstract][Full Text] [Related]
2. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Green DJ; O'Steen S; Lin Y; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Fisher DR; Nartea M; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; Orcutt KD; Wittrup KD; Press OW
Blood; 2018 Feb; 131(6):611-620. PubMed ID: 29158362
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
4. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
6. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI; Shenoi J; Frayo SM; Hamlin DK; Lin Y; Wilbur DS; Stayton PS; Orgun N; Hylarides M; Buchegger F; Kenoyer AL; Axtman A; Gopal AK; Green DJ; Pagel JM; Press OW
Clin Cancer Res; 2011 Dec; 17(23):7373-82. PubMed ID: 21976541
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Pagel JM; Kenoyer AL; Bäck T; Hamlin DK; Wilbur DS; Fisher DR; Park SI; Frayo S; Axtman A; Orgun N; Orozco J; Shenoi J; Lin Y; Gopal AK; Green DJ; Appelbaum FR; Press OW
Blood; 2011 Jul; 118(3):703-11. PubMed ID: 21613259
[TBL] [Abstract][Full Text] [Related]
10. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
Green DJ; Pagel JM; Nemecek ER; Lin Y; Kenoyer A; Pantelias A; Hamlin DK; Wilbur DS; Fisher DR; Rajendran JG; Gopal AK; Park SI; Press OW
Blood; 2009 Aug; 114(6):1226-35. PubMed ID: 19515724
[TBL] [Abstract][Full Text] [Related]
11. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
12. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Forero-Torres A; Shen S; Breitz H; Sims RB; Axworthy DB; Khazaeli MB; Chen KH; Percent I; Besh S; LoBuglio AF; Meredith RF
Cancer Biother Radiopharm; 2005 Aug; 20(4):379-90. PubMed ID: 16114986
[TBL] [Abstract][Full Text] [Related]
17. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
Kroger LA; DeNardo GL; Gumerlock PH; Xiong CY; Winthrop MD; Shi XB; Mack PC; Leshchinsky T; DeNardo SJ
Cancer Biother Radiopharm; 2001 Jun; 16(3):213-25. PubMed ID: 11471486
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
O'Donnell RT; DeNardo SJ; DeNardo GL; Miers L; Lamborn KR; Kukis DL; Meyers FJ
Prostate; 2000 Aug; 44(3):187-92. PubMed ID: 10906734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
